Optimizing the workflow for therapeutic viral vectors – upstream and downstream

As an industry we can make viral vectors. Now it is time to refine processes to achieve the yield and quality needed to support research, development, and commercialization while controlling costs. Collectively, small changes in unit operations can have a big impact on developing a process that is efficient and scalable, yet flexible enough to adapt over time.

Watch this on demand webinar with Dr Spencer Hoover, Director of Process and Analytical Development – Centre for Advanced Therapeutic Cell Technologies, Centre for Commercialization of Regenerative Medicine (CCRM), Dr Lesley Chan, Senior Scientist, Vector Process Development, Bluebird Bio and Francesca Bellintani, Downstream Process Development Manager, MolMed.

• Understand the key challenges with viral vector production and identify the major bottleneck steps
• Find out how industry leaders are currently addressing issues with current production volumes and titers, and seeking to alleviate the capacity crunch
• Get updated on the latest advances with stable producer cell lines and improved purification techniques
• Gain high-level regulatory insights around viral vector bioprocessing

[#speakersPlaceHolder]

Spencer Hoover

Principal at Independent

Lesley Chan

Senior Scientist at bluebird bio, Inc

Dr. Lesley Chan is a Senior Scientist in Vector Process Development at bluebird bio. At bluebird bio, she is focused on developing and implementing lentiviral vector production processes to support their clinical and commercial programs. This includes the development of a next-generation lentiviral vector manufacturing platform using stable cell lines. Prior to joining bluebird bio, Lesley worked at CCRM as a development scientist, where she developed processes for the expansion of multipotent or pluripotent stem cells in stirred tank bioreactors. She holds a PhD in Bioengineering from the National University of Singapore and an M.Sc. in Engineering Management from Tufts University.

Francesca Bellintani

Downstream Vector Development Manager at AGC Biologics

Francesca Bellintani is Downstream Process Development Manager at MolMed. Biologist by education, she holds a degree in Biology from University of Milan working on overproduction and purification of recombinant proteins and she specialised in Biochemistry, working on Phage display at Cambridge University. With a demonstrated history of working in the biotechnology industry, she joined MolMed in 2007 and worked in the Development Unit with growing responsibilities. She has strong operations expertise in the development of processes for the purification of proteins and retroviral/lentiviral vectors using chromatography and tangential flow filtration techniques. her role involves supervision of a multidisciplinary team of scientists on projects from development to early phase GMP manufacturing.

Watch now

SPEAKERS

Spencer Hoover

Principal at Independent

Lesley Chan

Senior Scientist at bluebird bio, Inc

Francesca Bellintani

Downstream Vector Development Manager at AGC Biologics

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 71

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 42

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 36

Days

Register

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity

22 May

in 35

Days

Register

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

21 May

in 34

Days

Register